Evommune Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Evommune, Inc. (EVMN) - Annual data in millions USD
BreakdownFY 2024FY 2023
Period EndingDec 2024Dec 2023
Operating Activities
Net Income-66.81-34.05
Depreciation & Amortization1.291.00
Stock Based Compensation0.001.48
Change in Working Capital7.423.34
Change in Accounts Payable6.510.13
Change in Other Working Capital0.920.22
Other Operating Activities-0.100.00
Net Cash from Operating Activities-58.20-29.97
Investing Activities
Capital Expenditures-0.09-0.12
Purchases of Investments-90.26-48.32
Sales/Maturities of Investments86.350.00
Net Cash from Investing Activities-3.99-48.43
Financing Activities
Common Stock Issued49.840.01
Other Financing Activities-0.420.00
Net Cash from Financing Activities49.4263.75
Summary
Net Change in Cash-12.77-14.65
Cash at Beginning of Period29.020.00
Cash at End of Period16.250.00
Free Cash Flow-58.28-30.09
Supplemental Disclosures
Interest Paid0.030.06